<DOC>
	<DOCNO>NCT01069926</DOCNO>
	<brief_summary>To assess pharmacokinetics AZD1656 , metabolite , type 2 diabetes mellitus patient vary degree renal impairment compare result patient normal renal function .</brief_summary>
	<brief_title>To Assess Pharmacokinetics AZD1656 Its Metabolite Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients clinical diagnosis T2DM least 1 year , treat OAD insulin Calculated MDRD GFR base Screatinine enrollment fall within 4 category : mild , moderate , severe normal Clinically significant progression current disease clinically relevant trauma , judge Investigator , within 2 week first administration IP Clinically significant neuropathy accord Investigator . However subject diabetic neuropathy clinically significant accord Investigator may include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Diabetes</keyword>
</DOC>